By Medical Science Correspondent
In the landscape of modern gastroenterology, the standard protocol for diagnosing Eosinophilic Esophagitis (EoE)—a chronic, immune-mediated esophageal disease—has long involved a "catch-all" approach to endoscopy. For years, clinicians have routinely performed gastric and duodenal biopsies alongside esophageal sampling during index endoscopies, often driven by the desire to rule out concurrent gastrointestinal pathologies.
However, a groundbreaking study published in the May 2026 issue of Diagnostics challenges this long-standing clinical habit. The study, titled "Do Routine Gastric and Duodenal Biopsies Add Value in Patients with Eosinophilic Esophagitis? Evidence from a Large Single-Center Case Registry," suggests that the practice of universal extra-esophageal sampling may be an inefficient use of resources with little clinical impact on patient outcomes.
The Core Investigation: Shifting the Paradigm
The research team, led by Elena Grueso-Navarro and Alfredo J. Lucendo from the Department of Gastroenterology at the Hospital General de Tomelloso, Spain, sought to address a persistent controversy: Does the diagnostic yield of routine biopsies in the stomach and duodenum justify the procedural time, cost, and potential patient discomfort?
The investigators analyzed data from the EoE CONNECT registry, a robust repository of patient information spanning from 2001 to 2024. By reviewing a cohort of 340 patients—comprising both pediatric and adult populations—the researchers aimed to determine whether symptoms or endoscopic appearance were reliable predictors of pathological findings in the lower GI tract.
The findings were stark: While 88.5% of the study participants underwent both gastric and duodenal biopsies, the overall diagnostic yield for findings unrelated to the esophagus was merely 20.9%. More importantly, the vast majority of these findings were related to Helicobacter pylori-associated gastritis (18.8%), while clinically significant, life-altering diagnoses like celiac disease (0.6%) and eosinophilic gastritis (0.3%) were exceptionally rare.
Chronology of the Study and Data Collection
The study represents a comprehensive look back at over two decades of clinical practice. The timeline of the research and the patient data can be summarized as follows:
- 2001–2024 (Data Collection Period): The study draws from the EoE CONNECT registry, tracking the diagnostic journeys of 340 patients over 23 years. This long-term scope allows for a unique view of how diagnostic patterns have shifted and how often incidental findings actually impacted patient care.
- March 31, 2026 (Submission): The research team submitted their findings to Diagnostics, aiming to influence clinical guidelines by providing empirical evidence for a more selective approach.
- April 29, 2026 (Revision): Following peer review, the authors refined their analysis, strengthening the correlation between age, symptoms, and the utility of biopsies.
- May 7, 2026 (Acceptance): The editorial board accepted the paper, recognizing its significance in the context of evidence-based medicine and healthcare efficiency.
- May 9, 2026 (Publication): The study was formally published, igniting a conversation about the necessity of procedural minimalism in gastroenterology.
Supporting Data: Why Routine Sampling May Be Unnecessary
The study’s data offers a clear mandate for change. When analyzing the relationship between clinical presentation and biopsy results, the researchers found that neither the patient’s reported symptoms nor the endoscopic appearance of the stomach and duodenum served as reliable predictors of underlying pathology. The statistical analysis returned a p-value of 0.11, indicating no significant association between observed abnormalities and the necessity for biopsy.
Key Data Points:
- Total Cohort Size: 340 patients.
- Pediatric Participation: 35.7% of the cohort were children, ensuring the study’s findings are applicable across the lifespan.
- Incidence of Significant Findings: Only 0.9% of the cohort received a diagnosis of high clinical consequence (celiac disease or eosinophilic gastritis).
- Incidental Findings: The majority of positive biopsies (18.8%) were limited to H. pylori infections.
- Age Factor: While older patients were statistically more likely to have positive extra-esophageal biopsies (p < 0.001), the nature of these findings rarely necessitated a change in the overarching management of the patient’s EoE.
The researchers also noted that in follow-up biopsies, many of the initially identified pathological findings—particularly H. pylori gastritis—resolved. This suggests that the initial biopsy was often identifying transient issues rather than chronic, undiagnosed conditions that required urgent intervention.
Clinical Implications: A Call for Selective Biopsies
The implications of this study are profound for gastroenterologists worldwide. The "universal biopsy" approach, while well-intentioned, appears to provide a very low return on investment in terms of patient health.
Moving Toward Selective Sampling
The authors argue that gastroenterologists should shift toward a selective approach. Instead of performing routine gastric and duodenal biopsies for every patient suspected of having EoE, physicians should consider sampling only when:
- There is a high clinical suspicion of concurrent disease based on patient history.
- Visible, significant abnormalities are observed during the endoscopic procedure that suggest conditions like celiac disease.
- The patient exhibits specific, persistent symptoms that cannot be explained by EoE alone.
By reducing the number of unnecessary biopsies, medical institutions can decrease procedural time, lower costs, and minimize the risk of complications associated with tissue sampling. Furthermore, this shift aligns with the broader movement in modern medicine toward "Choosing Wisely"—the philosophy of reducing unnecessary medical interventions to improve the quality of care.
Official Responses and Future Outlook
The gastroenterology community has begun to take note of these findings. While it is early in the post-publication phase, the consensus among many specialists is that the "one-size-fits-all" approach to endoscopy is becoming increasingly outdated.
Critics of the study might argue that the risk of missing a rare condition like celiac disease is too high to justify abandoning routine biopsies. However, the study’s authors emphasize that the prevalence of these conditions in the EoE population does not appear to be high enough to warrant the universal burden of routine screening.
"We are not suggesting that clinicians ignore the rest of the GI tract," the authors noted in their discussion. "Rather, we are suggesting that the clinical decision to biopsy should be grounded in evidence and patient-specific needs, rather than a reflex action performed out of habit."
As the medical community digests these results, it is likely that professional societies may revisit their guidelines regarding index endoscopy for EoE. If future clinical trials corroborate these findings, the "new normal" for EoE diagnostics could see a significant reduction in biopsy rates, shifting the focus back to the esophagus—the primary site of the disease.
Conclusion
The study led by Grueso-Navarro et al. serves as a timely reminder that more data is not always better data. In the context of Eosinophilic Esophagitis, the routine biopsy of the stomach and duodenum provides little actionable information, creating a potential redundancy in diagnostic care.
By adopting a more selective, patient-centered approach, gastroenterologists can improve efficiency without compromising patient safety. As we look toward the future of digestive health, the evidence suggests that the most sophisticated approach is often the most targeted one. The findings published in Diagnostics are a critical step toward refining our clinical protocols and ensuring that we provide the highest standard of care based on robust, real-world evidence.
References:
Grueso-Navarro, E.; Úbeda-Vargas, V.; Juárez-Tosina, R.; Arias-González, L.; Laserna-Mendieta, E.J.; Lucendo, A.J. (2026). "Do Routine Gastric and Duodenal Biopsies Add Value in Patients with Eosinophilic Esophagitis? Evidence from a Large Single-Center Case Registry." Diagnostics, 16(10), 1446. https://doi.org/10.3390/diagnostics16101446
About the Author
